ProCE Banner Activity

Understanding an Increasingly Complex Treatment Landscape in Urothelial Carcinoma: Guidance for Frontline Oncology Practitioners

Slideset Download
Review slides with commentary in slidenotes from pharmacist and nursing experts on patient counseling, monitoring, and managing adverse events associated with avelumab, enfortumab vedotin, and erdafitinib in urothelial carcinoma.

Released: January 11, 2021

Expiration: January 10, 2022

No longer available for credit.

Share

Faculty

Kinjal Patel

Kinjal Patel, PharmD, BCOP

Clinical Oncology Pharmacist
Department of Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Susan Roethke

Susan Roethke, CRNP, MSN, AOCN, ANP-BC

Nurse Practitioner
Department of Hematology/Oncology
Genitourinary Medical Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Astellas Seattle Genetics

Janssen administered by Scientific Affairs

Faculty Disclosure

Primary Author

Kinjal Patel, PharmD, BCOP

Clinical Oncology Pharmacist
Department of Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Susan Roethke, CRNP, MSN, AOCN, ANP-BC

Nurse Practitioner
Department of Hematology/Oncology
Genitourinary Medical Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania